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Abstract
The difference between regional rates of HIV-associated dementia (HAD) in patients infected with different subtypes of HIV
suggests that genetic determinants exist within HIV that influence the ability of the virus to replicate in the central nervous
system (in Uganda, Africa, subtype D HAD rate is 89%, while subtype A HAD rate is 24%). HIV-1 nef is a multifunctional
protein with known toxic effects in the brain compartment. The goal of the current study was to identify if specific three-
dimensional nef structures may be linked to patients who developed HAD. HIV-1 nef structures were computationally
derived for consensus brain and non-brain sequences from a panel of patients infected with subtype B who died due to
varied disease pathologies and consensus subtype A and subtype D sequences from Uganda. Site directed mutation
analysis identified signatures in brain structures that appear to change binding potentials and could affect folding
conformations of brain-associated structures. Despite the large sequence variation between HIV subtypes, structural
alignments confirmed that viral structures derived from patients with HAD were more similar to subtype D structures than
to structures derived from patient sequences without HAD. Furthermore, structures derived from brain sequences of
patients with HAD were more similar to subtype D structures than they were to their own non-brain structures. The
potential finding of a brain-specific nef structure indicates that HAD may result from genetic alterations that alter the
folding or binding potential of the protein.
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Introduction
The ability to identify neurotropic strains of the Human
Immunodeficiency Virus type 1 (HIV-1) is relevant to many
different fields of HIV research. This is reflected in numerous
research articles that attempt to 1) explain viral evolution in the
central nervous system (CNS), 2) identify HIV-1 genotypes
associated with CNS viral compartmentalization, 3) assess
molecular diversity of various HIV-1 proteins and their functional
consequences in the CNS, and 4) develop treatments for
individuals suffering from the effects of HIV-associated dementia
(HAD). The CNS is a viral reservoir in which the primary HIV-
infected cell-type is the macrophage, a cell-type that is not targeted
by current antiretroviral therapies. HAD develops when HIV-
infected monocytes or macrophages can pass into the brain and
infect resident brain macrophages; next, infected macrophages
then release cytokines that attract more macrophages to sites of
infection and a self-inflammatory process transpires [1,2]. At
autopsy, patients with HAD display an abundance of HIV-
infected macrophages deep within brain tissues, particularly in the
frontal and temporal lobes. It is interesting that in some patients
without any trace of clinical HAD pathology, HIV DNA exists
within brain tissues. On the other hand, other HIV-infected
patients have no detectable HIV DNA in the brain at death [3,4].
These findings suggest that some HIV variants may be more
capable of entering the CNS, but are less pathogenic in the brain
environment, whereas other HIV variants might be more efficient
in both brain infiltration and in setting up the HAD self-
inflammatory macrophage environment. Another explanation for
the finding of HIV in the brain without HAD development, could
be late-stage HIV infiltration, which could arise from atheroscle-
rosis or breakdown of the blood brain barrier near death [3,5,6].
HIV is classified into numerous subtypes based on genetic
similarities. In 1999 Kanki et al. found that subtype A has a longer
AIDS-free survival than non-A (Kanki et al, 1999). Other studies
showed that subtype D has a shorter time to death and AIDS than
subtype A, C, or recombinant forms (Vasan et al, 2006); and in
subtype C, CCR5/non–syncytia-forming viruses are almost always
the dominant form even in late stages of infection (Tscherning et
al, 1998). In 2009, Sacktor et al. demonstrated that individuals in a
localized region of Uganda, Africa infected with subtype D HIV-1
had an 89% chance of developing HAD, while those infected with
subtype A had only a 24% chance of developing HAD [7]. A
report from Ethiopia suggested that HAD is infrequent in clade C
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association between HIV subtypes and neurological disease [8].
We recently reported that the HIV-1 nef protein evolves
differently in brain tissues from patients who develop HAD than
from patients who do not [3]. Given these observations, a viral
genetic link to HAD is possible; however, due to the extensive
diversity in the HIV genome within an individual and especially
between HIV-1 subtypes, the ability to identify a HAD-specific
virus based on DNA sequence data alone does not exist.
Several HIV proteins have been implicated in the development
of HAD, in particular nef, tat, env, vpu and the LTR
[9,10,11,12,13,14]. HIV-1 nef is a multi-factorial protein required
to maintain high viral loads [15]. The loss of nef function results in
delayed or absent AIDS progression [16,17,18]. It is the first
protein to accumulate following infection of macrophages and is
estimated to represent three-quarters of the viral load in the
infected cell [19]. Additionally, nef promotes the survival of
infected cells [20] and migration [21]. In the cell, nef can bind
MHC class II receptors, allowing it to interfere with a variety of
cellular process such as triggering rapid CD4 endocytosis,
targeting the trans-golgi network, activating phosphatidylinositol
3-kinases and lysosomal degredation [22,23]. Several studies have
showed that exposure of neuronal cell cultures to nef resulted in
neurotoxicity [24,25,26,27]. Within the brain of HIV-1-infected
patients, nef is found in both macrophages and astrocytes [28]. A
study by Ranki et al. found that astrocyte infection is associated
with moderate to severe dementia; additionally, the study found
that astrocytes preferentially express HIV nef and rev proteins and
that six out of seven patients with nef-positive astrocytes suffered
from moderate to severe dementia [29]. Other studies indicated
that stable expression of nef may alter growth properties of human
astrocytes [28] and that nef/LTR deleted viruses have either
diminished neurotropism or insufficient systemic viral replication
for entry into the CNS [30]. Olivieri et al. performed a genetic
analysis of nef that demonstrated the existence of adaptive
selection in the brain, thus suggesting altered requirements for
efficient replication of nef in macrophages or when exposed to
brain-specific immune selection pressures [31].
Considering the large body of work that has potentially linked
the HIV nef protein to HAD development, defined the effects of
nef and analyzed how nef amino acid variation may contribute to
its structural properties, our goal was to determine if clues to
dementia pathogenesis could be discerned from the three-
dimensional (3D) structure of the nef protein derived from patients
with and without HAD. We utilized 1153 sequences to generate
consensus sequences for brain and non-brain tissues from HIV-1
infected patients, including subtype A and D sequences from
Uganda. These consensus sequences were then used to compu-
tationally generate protein structures. Keeping in mind that the
nef protein is flexible in its natural environment, a snapshot of the
protein calculated in an identical environment from a cohort of
individuals displaying different disease pathogenesis could eluci-
date structure-function similarities that are not discernible by
viewing sequence information alone.
Methods
Samples
Frozen autopsy tissues from patients and accompanying
pathology records were obtained from the University of California
at San Francisco AIDS and Cancer Specimen Resource (ACSR)
(http://acsr.ucsf.edu). The tissues were obtained from patients
after appropriate written consent and after a de-identification
procedure was applied. Patient designations used throughout this
study were generated randomly as shorthand used by technicians
who performed the studies and do not correlate to patient
information. The ACSR is recognized by the Office of
Biorepositories and Biospecimen Research at the National
Institutes of Health as being HIPAA compliant and in accordance
with the ethical standards of the Declaration of Helsinki.
Additionally, all material was obtained under written approval
from the UCSF committee on human research. The UCSF
committee on human research approved the study.
Patients and tissues
Extensive details concerning patient tissue samples utilized in
the current study have been published previously [32]. Briefly,
patients AM and IV developed metastatic AIDS-related lympho-
ma (ARL), patients GA and CX developed progressive HAD,
patient BW developed ARL, including meningial lymphoma,
patient DY had suffered from recurring Mycobacterium avium
complex infection (MAC) for years and developed an aggressive
form of HAD in the weeks prior to death.
Quantitative PCR
A quantitative polymerase chain reaction (QPCR) was used to
identify if HIV DNA was present in significant amounts in the
brain tissues from each patient. First, 50 ng of genomic DNA was
prepared by QIAamp DNA Mini Kit (QIAGEN company,
Valencia, CA) and quantified using ultra-violet spectrometry at
an absorbance of 260 nm (Nano-DropH ND-1000 UV-Vis
Spectrophotometer, NanoDropTechnologies, Wilmington, Dela-
ware). Next, HIV copy number/genomic equivalent within each
tissue was calculated by QPCR using primers SK38 (59-ATA ATC
CAC CTA TCC CAG TAG GAG AAA T-39) and SK39 (59-TTT GGT
CCT TGT CTT ATG TCC AGA ATG C-39) yielding a 110 bp
fragment of the gag sequence. The single-copy human c-jun gene
was used as genomic equivalent standard for quantitation
purposes. The amplification protocol comprised one cycle
denaturation at 95uC for 10 minutes, followed by 30 cycles of
95uC for 15 s, 60uC for 5 s, and 72uC for 12 s (Roche’s FastStart
NA Master SYBR Green 1 Kit, Roche Applied Science,
Indianapolis, IN). 1 HIV copy number/5000 cell equivalents
was used as a cut-off, with all values higher considered HIV-1
positive. This ratio had replicates within 15% coefficient of
variation; a greater amount was associated with intra-assay noise.
This approach indicated that four of the six patients had QPCR
amplifiable amounts of HIV in the brain at the time of death (GA,
CX, BW and DY).
Sequences
Amplification, cloning, and sequencing of HIV DNA were
performed as follows. Genomic DNA was extracted from 10–
30 mg of each tissue using the QIAmp DNA Mini Kit from
Qiagen according to the manufacturer’s instructions. A 3.3 kb
HIV fragment, extending from the 59 env to the 39LTR U3
domain was amplified by PCR using the primers EnvF1 (AAC ATG
TGG AAA AAT AAC ATG GT) and NefR1 (ACT TDA AGC ACT
CAA GGC AA) under the following conditions: an initial
denaturation step of 94uC for 5 min followed by 35 cycles of
94uC for 30 sec, 55uC for 30 sec, 68uC for 3 min 20 sec, and a
final extension at 68uC for 8 min, in 50 ml volume using 600 ng of
template DNA, 10 mlo f1 0 6 buffer (Invitrogen), 10 mM
deoxynucleoside triphosphates (Invitrogen) 60 mM of each primer,
and 2.5 units of Invitrogen Platinum-Taq polymerase. Products
were cloned into the pCR2.1-TOPO vector according to the
manufacturer’s instructions and the resultant colonies were
screened for the proper insert using the PCR protocol described
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Hayward, CA. For each patient five to seven tissues were studied.
Approximately 20–30 sequences were derived from each tissue
(Table 1, Genbank accession numbers GQ868779-GQ869380). In
addition, all nef subtype D (67 sequences) and subtype A (55
sequences) sequences derived from patients in Uganda, Africa
were downloaded from the public domain HIV Sequence Data
Base at the Los Alamos Laboratories (www.hiv.lanl.gov). Sequenc-
es were aligned using Clustal with the MEGA 4.0 software
package (http://www.megasoftware.net/) and a phylogenetic tree
using all protein sequences was calculated using the neighbor-
joining method and the PAM matrix (Figure S1) and a bootstrap
value of 500 replicate samplings. Protein sequences were used in
the analysis so that only nonsynonymous DNA mutations would
be observed in the tree and provide a view of the evolutionary
distance between patients and subtypes at the functional level.
Phylogenies were visualized using Figtree (http://tree.bio.ed.ac.
uk/software/figtree/). Next, a consensus nef sequence was
generated for brain and non-brain sequences for each patient
and subtype A and D populations using the program Seqpublish at
the Los Alamos HIV Data Base (www.hiv.lanl.gov). Consensus
sequences were aligned to the molecular clone HXB2 (Figure 1).
Calculation of disease-associated point mutations
Potential disease-associated point mutations were calculated
using the Site Directed Mutator (SDM, http://mordred.bioc.cam.
ac.uk/,sdm/sdm.php). SDM compares structures in order to
determine if point mutations would significantly modify the
Figure 1. Consensus Sequence Alignment. Consensus sequences were constructed using the program Seqpublish for sequences derived for all
patients. For the patients with brain infection, consensus sequences were generated independently for brain and non-brain sequences. Capitol letters
indicate positions conserved at 95%, lowercase letters are positions conserved at 50–95% and a question mark indicates non-conserved positions.
Dashes indicate identity to HIV clone HXB2. Periods indicate gapped positions. The blue highlighted positions correspond to mutable amino
positions potentially associated with disease pathology as calculated with SDM. The yellow highlighted position, immediately prior to position 101i s
necessary for the mutation H to Y to be significantly destabilizing. The purple highlighted positions show that a glycosylation motif exists in all non-
brain structures that may be used for structural, rather than functional purposes. Further information on these positions can be found in Table 1.
Secondary structure information is shown above the sequence. Asterisks (*) indicate positions necessary for SH3 binding. The carrots (‘) indicate the
domain associated with chemokines binding. The At symbols (@) indicate a dileucine binding motif associated with AP-2 binding.
doi:10.1371/journal.pone.0016659.g001
Table 1. Sequences used for consensus sequence building.
Sequence Population Number of Tissues
Number of
sequences
CX brain 7 147
CX non-brain 2 49
GA brain 3 79
GA non-brain 2 50
BW brain 5 119
BW non-brain 1 36
DY brain 5 103
DY non-brain 2 49
AM non-brain 10 231
IV non-brain 10 168
Subtype D 1 67
Subtype A 1 55
doi:10.1371/journal.pone.0016659.t001
HIV Proteins Associated with Dementia Pathogenesis
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16659structure using a statistical potential energy function developed by
Topham et al. [33]. SDM has been successfully used to identify
disease-associated modifications within protein structures [34].
The program calculates the DDG, which is the difference in free
energy in the unfolding of the changed vs. unchanged positions
within structures. A value less than -1.0 indicates that an amino
acid substitution significantly modifies the structure and would
unfold at lower temperature.
Generation of nef 3D structures
A structural model of the complete nef protein was assembled
from partial structures published in the Research Collaboratory
for Structural Bioinformatics (RCSB) Protein Data Bank (PDB) as
follows: a core domain structure spanning residues 56–159 and
175–206 (numbering relative to the HIV reference sequence
HXB2; RCSB PDB accession number 2NEF]); and an anchor
domain structure spanning residues 2–57 (RCSB PDB accession
number 1QA5). The core and anchor domain were merged using
Swiss-PDB Viewer and local energy minimization was performed
using UCSF Chimera (http://www.cgl.ucsf.edu/chimera/). The
composite structure was further modified using the same methods
for the insertion of 15 residues to restore the disordered loop
bounded by core residues E and D and performing local energy
minimization of this loop. Further energy minimization was
carried out using GROMACS (http://www.gromacs.org). We
hypothetically ‘immersed’ the molecule in an aqueous solution
bounded by a cubic box, and performed energy minimization of
this system using a simulated annealing method (with annealing
temperatures 425K, 375K, 325K, 275K, 245K, and 203K
scheduled at time points 0, 100, 200, 300, 400, and 500
picoseconds, respectively) to a force tolerance of 10‘-3 kJ mol
nm. Lacking topological information about myristol, it was
necessary to omit the myristolated N-terminal methionine residue
from the model. Next, we replaced six water molecules with
sodium ions in order to neutralize the net negative charge of the
system and repeated the energy minimization step. By modifying
residues in the Swiss-PDB Viewer and performing energy
minimization in GROMACS, we generated patient structures
from the base structure by varying the number of solvent
molecules replaced by charged ions as necessary to neutralize
the system.
Visualization and alignment of structures
The program PyMOL (http://www.pymol.org/) was used to
visualize and color structures as shown in Figure 2 and Figure 3.
Distance analysis
The variation between each patient sequence population to
subtype A and subtype D populations were calculated using
MEGA 4.0 (Figure 4A) and the Tamura 3-parameter molecular
model using 1000 bootstrap replicates.
Structural variation
The deviation between consensus 3D protein structures was
calculated using PyMOL. PyMOL aligns by atomic coordinates
and calculates the minimum root square mean deviation (RMSD)
between aligned atoms. The RMSD is a well-known standard for
measuring structural similarity between two structures. Since
PyMOL will not align highly divergent residues, the number of
aligned atoms used to calculate the RMSD for each alignment was
obtained to determine if a similar number of atoms were aligned in
each comparison (Figure 4B). A box and whisker plot summarizing
the comparison of all patients’ structures to each other (37
structural comparisons) was generated (Figure 5). In the first plot
in Figure 5 (HAD vs. HAD), the range of the RMSD values for
comparing subtype D, CX and GA is shown. In the second plot
(non-HAD vs. non-HAD), the range of the RMSD values for
comparing structures subtype A, BW, DY, AM and IV is shown.
In the third plot, the range of the RMSD values for all structural
comparisons is shown. All graphs were generated using the
program DataGraph version 2.1.1 (http://www.visualdatatools.
com/DataGraph/).
Results
Phylogenetic Analysis
Phylogenetic analysis of all data used in the study showed that
the sequences from each patient were unique to that patient and
clustered in individual clades on the tree (Figure S1). In addition,
subtype A and D sequences formed distinct clades on the tree that
were unrelated to patient sequence populations. Phylogenetic
analysis of nef nucleotide sequences for each patient has been
previously published and showed that there were some significant
subpopulations within patient datasets, especially between brain
and non-brain sequences for patients GA and CX [3].
Consensus Sequence Alignment and Mutational Analysis
For the purpose of discussion, the term ‘‘brain sequences/
structures’’ refers to sequences from patients who had HIV within
the brain at the time of death and no signs of progressive HAD
(BW, DY), ‘‘HAD sequences/structures’’ refers to patients who
died due to long-term progressive HAD (GA, CX), and ‘‘non-
HAD sequences/structures’’ refers to patients who did not have
amplifiable amounts of HIV within the brain at the time of death
and showed no sign of brain disease (AM, IV). Several positions
along the alignment appeared related to brain, HAD and non-
HAD sequences. Using the program SDM, we identified the
mutations that would significantly alter the Gibbs Free Energy
(DG); the positions are highlighted in the alignment shown in
Figure 1. The changes in DG for the non-HAD vs. HAD are
shown in Table 2.
Positions 83, 101, and 162 displayed strong signatures among
the groups. At position 83, all of the HAD and brain patients
contained a glycine (G), whereas all non-HAD patients contained
an alanine (A). At position 101, all non-HAD sequences contained
a tyrosine (Y), all brain sequences contained a histidine (H), and
most HAD sequences also contained an H. An interesting disease-
associated position was found at position 162, which occurs in the
center of the nef loop domain; all of the HAD patients and the
subtype D sequence contained a Cysteine (C), one of the brain
patients contained a C and none of the non-brain sequences
contained a C in this position. More interesting is that a C
substitution results in the elimination of a glycosylation motif
(NXT or NXS, where X is any amino acid except P). Although nef
is not glycosylated during HIV infection, the substitution
introduces a residue that is free to interact by di-sulfide bonding
with cysteines within the protein or with other proteins in the
environment. Patient BW did not have a C in this position;
however, he did not have a glycosylation motif either. In patient
BW brain structures, the DDG of a mutation to a C is -7.359,
much higher than the non-brain patients. At position 181 the
mutation of a valine (V) or methionine (M) to a glutamine (Q) is
destabilizing. All of HAD sequences had a V or an M in this
position and all of the non-HAD sequences contained a Q. Brain
sequences were again mixed with one patient containing the V
residue and one patient containing the Q residue.
HIV Proteins Associated with Dementia Pathogenesis
PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e16659Figure 2. 3D HIV-1 nef tertiary structure (Panel A) and potential disease-associated mutations (Panels B and C). In Panel A, the colors
correspond to the secondary structure shown above the alignment in Figure 1. A cartoon format is shown on the left and the structure displayed as
the surface that would be traced out by water in contact with the protein at all possible positions on the right. Panels B and C show different views of
the nef protein. Disease associated mutations are shown in purple and are numbered according to Table 1. Panel A shows a surface view of the
protein with positions 162, 71, and 83 highlighted and identifies the location of the SH3 pocket. Panel B shows a mesh view, with the cartoon
structure superimposed; the inset boxed in red shows the relationship of positions 101 and 181 in the 3D structure, which appear on opposite
strands of the beta sheet formation.
doi:10.1371/journal.pone.0016659.g002
Figure 3. Representative brain and non-brain structures. Structures derived from patient CX brain consensus sequence (Panel A) and patient
AM consensus sequence (Panel B) are shown for comparison of brain and non-brain structure. Signature positions are yellow, labeled according to
the alignment in Figure 1 and shown as spheres with the surface superimposed.
doi:10.1371/journal.pone.0016659.g003
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among the three groups, some were less convincing, yet still
notable. In patient GA at position 71 there was a mixture of R and
lysine (K) in HAD and brain sequences. In the same position, one
non-brain patient contained all R while the other contained a
mixture of threonine (T), K and R. Although the change from and
R or K to a T is considered destabilizing, the signature in our
study population is only weakly associated to the brain or HAD
phenotype. Primarily the occurrence of a T in this position in any
sequence is interesting because it is necessary for SH3 binding.
HIV-1 nef structural analysis
Figure 2A shows the structure of the complete nef protein
obtained by combining PDB structures 2NEF (transmembrane
domain) and 1QA5 (myristoylation domain). On the left is the
backbone representation and on the right is the surface
representation with the same color scheme. The figure shows that
much of the tertiary structure is exposed to the surface of the
protein with particular exposure of the nef loop domain (red). In
Figure 2B (left panel), the potential signature amino acids 83, 71,
and 162 are seen to some extent on the surface of the molecule.
Positions 71 and 83 are shown within the well-characterized SH3
binding pocket of nef [35]. In Figure 2B (right panel), the structure
is shown as a mesh so that it is possible to visualize through the
structure and observe the close proximity of positions 181 and 101.
These positions are directly adjacent to each other in the
hydrophobic core structure of the internal anti-parallel beta sheet
of nef (Figure 2B, right panel). Considering that both of these
mutations can alter the structure, this finding may indicate that the
sites co-evolve to maintain a specific protein conformation.
Figure 3 shows a comparison of brain structure derived from
patient CX consensus sequence to a non-brain structure derived
from patient AM’s consensus sequence. The rotation of the
structure is different from that in Figure 2 so that all signature
positions (yellow spheres), and their relationship to each other can
be seen clearly.
Distance analysis
The distance between patient subtype B sequence populations
from subtype D and A populations was assessed to determine if
there was any significant difference between the populations at the
amino acid level (Figure 4A). Overall, no significant genetic
difference at the nucleic acid level between subtype A and D to
patient sequence populations was found. The establishment of no
significant genetic distance between subtype B to subtype D and A
sequence populations is important when considering the results of
structural alignments in the following section.
Structure alignments
Figure 4B shows the RMSD and number of atoms aligned in
the comparison of patients’ structures to subtype A and D
structures. Overall, the number of atoms aligned (hashed bars) in
each analysis did not vary significantly (p=.0.0001), thus
indicating that the alignments across various structures were of
equal integrity. In Figure 4B (left panel), HAD structures are
significantly more related to the subtype D structure than non-
HAD structures are related to the subtype D structure (p=.0.05).
In addition, a comparison of Figure 4B (left panel) and 4B (right
panel) indicates nef structures derived from patient’s brain tissues
with HAD were significantly more similar (p=.0.01) to the
consensus subtype D ‘‘dementia’’ nef structure (RSMD =0.13)
than to the consensus subtype A ‘‘non-dementia’’ nef structure
(RSMD=0.34). There was no statistical difference between non-
HAD structures aligned to either subtype D or A structures
(p=1.0). An alignment of patient CX and GA brain structures also
had a very low RMSD value of 0.11 (data not shown in Figure 4).
In Figure 4C we compared the brain to non-brain structures
within each patient to assess the within-patient structural variation.
Interestingly, the two HAD patients varied almost two-fold
between their brain and non-brain structures than the non-HAD
patients (BW and DY). Furthermore, CX brain structure is slightly
closer to the subtype D structure (RMSD =0.15) than to his non-
Figure 5. Box and Whisker plot comparing RMSD values from three populations of structures. The diagram describes the two groups of
data through six statistical summaries: 1) the sample minimum, 2) lower quartile (Q1), 3) median, (4) upper quartile (Q3), 5) sample maximum and 6)
outliers. The spaces between the different parts of the box indicate the spread of the data.
doi:10.1371/journal.pone.0016659.g005
Figure 4. Variation among sequence populations and consensus structures. In panel A, the distance between patient sequences was
compared to subtype D (light blue bars) and subtype A (dark blue bars) using Mega 4.0. Standard error bars are shown in red. Panel B displays the
RMSD values for consensus patient brain structures aligned to consensus subtype D and consensus subtype A structures. Patient IDs are on the X-
axis. Each graph provides the RMSD (left y-axis) and number of atoms compared (right y-axis) in each structural alignment. In Panel C RMSD values for
the comparison of brain vs. non-brain structures within each patient are provided. Patient IDs are on the x-axis.
doi:10.1371/journal.pone.0016659.g004
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distance between his brain and non-brain structure (RMSD
=0.22) as compared to his brain and subtype D structure (RMSD
=0.13). Overall, the results from structural alignments showed
that HAD derived structures from the brain were more related to
subtype D structures than the non-HAD structures. This result is
quite interesting considering that at the genetic level, no significant
difference between HAD and non-HAD sequences to subtype A or
D was found.
In Figure 5, 3D structures from all patients were aligned to each
other resulting in 37 RMSD values that describe the overall
variation between structures in patients with varied disease
pathologies. The results were plotted in a box and whisker plot
and the results indicated that HAD structures are much more
similar to each other than non-HAD structures are similar to each
other. In addition, the results show that when HAD structures are
compared to non-HAD structures, an even larger spread of data
occurs.
Discussion
In this study we computationally generated and compared HIV
nef structures from patients who died due to different primary
HIV-associated pathologies. In particular, we were interested in
two patients who died due to HAD and questioned if they
harbored unique HIV nef structures within the macrophage-
associated tissues of the brain. In an earlier study, we noted that
many HIV-infected patients did not have significant amounts of
HIV within brain tissues at death [4]. Other patients have HIV
within the brain, but do not develop symptoms related to HAD.
Because of the multiple functions associated with the HIV nef
protein in the brain: 1) neuronal degeneration [36], 2) the
production of cellular cytokines [37] and, 3) the potential
interference of cellular pathways involved in central nervous
system integrity [10], we utilized the nef sequence in the current
analysis. HIV-1 nef modulates signaling in infected and bystander
macrophages, thereby facilitating disease progression. Geyer et al.
and Gerlach et al. made several important findings concerning the
structure of the nef protein: 1) the structure of nef is somewhat
flexible, with several well-defined regions that control many of its
functions, including a myristoylation domain that allows the
protein to anchor to cellular membranes, a loop within the core
domain designated for signaling and structural integrity and a
second flexible loop for trafficking and internalization, 2) flexible
regions form large surfaces of the protein that are readily
accessible for interactions and are capable of undergoing
important conformational changes and 3) the less-structured
nature of the flexible regions correlates with a higher degree of
sequence variability [38,39].
A number of cellular functions associated with macrophages
have been assigned to the nef protein, including inhibition of
apoptosis, sustained viral transcription, production of pro-
inflammatory cytokines and chemokines and expression of tumor
necrosis factor (TNF) on macrophages [40]. Costa et al. found a
nef consensus motif that binds the actin cortical patch component
(AIP1) in vitro and in vivo [41]. AIP1 is a critical intermediate in the
formation of multivesicular bodies (MVBs) that play an important
role in the budding and release of viruses from infected cells. This
function of nef was reproduced in primary macrophages, where
nef proteins led to increased release of new viral particles from
infected cells [41]. In addition, HIV-1 nef binds to the
macrophage-specific Src tyrosine family member Hck through
its SH3 domain, resulting in kinase activation that is capable of
transforming fibroblasts [42,43]. The Nef–Hck interaction may be
essential for macrophage-tropic HIV replication and AIDS
pathogenesis [43,44]. A full list of published HIV-1 nef
interactions can be found at http://www.ncbi.nlm.nih.gov/
RefSeq/HIVInteractions/nef.html.
In a healthy state, the brain is void of T- and B-lymphocytes and
even when a patient is HIV-infected, little, if any, infiltration of
immune cells into the brain other than monocytes and
macrophages occurs. Other cells infected by HIV when it enters
the brain are astrocytes [29,45]. Neuronal cells are not infected
with HIV, but cellular by-products produced by HIV-infected
macrophages affect neurons, resulting in cognitive impairment.
Potential HIV nef interactions are likely more restricted in the
brain compartment than in tissues associated with the lymphatic
system. With the task of crossing the blood-brain barrier (BBB) and
limited cell types to infect, it seems feasible that only certain
genotypes of HIV are capable of successfully infecting resident
brain macrophages and, furthermore, only a subset of these
genotypes have acquired the ability to induce the macrophage-
associated HAD cascade within that particular cellular environ-
ment.
In this study we found some brain signatures that may affect
protein folding and also a strong relationship between subtype B
brain structures from patients with HAD and a subtype D
consensus structure generated from 55 sequences originating from
individual patients in Uganda, where infection with subtype D
results in an 89% risk of developing HAD [7]. Interesting amino
acid substitutions occurred in HAD viruses that may not have
been obvious without mapping them to the 3D structures. The
interaction between nef and SH3 is important for enhancement of
virion infectivity and in MHC-I downregulation but not in
downregulation of CD4 [46,47,48] and the only structure
generated to date that shows the nef-SH3 interaction has an
alanine at position 83, whereas all of our patients with brain
infection had a glycine in this position. The DDG of an A to a G is
significant and could result in a gain-of-function for either SH3
binding or another unknown nef functional advantage. Glycine
has more conformational freedom than any other amino acid in an
unfolded protein; however, it has only one conformation in the
folded protein and this alone could account for the brain specificity
of the protein. The finding of disease-associated substitutions that
are directly adjacent (positions 101 and 181) in the hydrophobic
core structure of the internal anti-parallel beta sheet and a non-
bonded cysteine residue in the flexible loop that is accessible for
interactions is a new discovery. Because one of the core’s primary
functions is structural integrity, these substitutions could generate a
final structure with modifications significant enough to make them
Table 2. Potential disease-associated mutations in HIV nef.
Position Mutation DDG
1 Alter Structure?
71 R/T 22.727 Yes
71 K/T 21.003 No
71 R/K 20.302 No
83 A/G 22.851 Yes
101 H/Y
2 23.864 Yes
162 S/C 25.587 Yes
181 M/Q 22.465 Yes
181 V/Q 22.834 Yes
181 M/V 20.646 No
doi:10.1371/journal.pone.0016659.t002
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ally, position 101 is within a domain required for chemokine
induction [49]. Chemokines act as immuno-inflammatory medi-
ators and have an important role in normal brain function [50].
Cells secrete nef [51,52]; therefore, the cysteine mutation at
position 162 could bind extracellular proteins. Alternatively,
disulfide bridges are also formed in the endoplasmic reticulum,
which is the first compartment of the secretory pathway [53]. This
position also falls within a dileucine binding motif that can bind
AP-2 and substitutions here could reduce both AP-2 binding and
CD4 downregulation [54]. A glycosylation motif was eliminated in
nef with the cysteine substitution. Although glycosylation of nef
does not occur during HIV-infection, it is a factor considered in in
vitro assays for vaccine development [55]. Additionally, since the
one brain patient that did not have a cysteine at position 162 also
did not have a glycosylation motif, it may be that the asparagine-
asparagine-serine motif provides a structural rather than function-
al significance.
Comparison of closely related structures is useful in under-
standing how proteins accommodate slight alterations in amino
acid sequences and the analysis of such changes is vital to the
identification of protein attributes that could contribute to disease
or treatment. Despite considerable amino acid variation between
HIV subtypes, the finding that subtype B nef protein structures
derived from brain tissues in two patients are more similar to
Uganda subtype D structures than to the same patients’ HIV nef
structures derived from their non-brain tissues provides further
evidence that a disease-associated virus exists. Although a
considerable amount of brain derived sequence data exists within
the public sector, relatively few HIV-nef sequences from well
documented cases of HAD exist; we found only 112 sequences
derived from HAD patients and only 41 of these were extracted
from brain tissues from a total of 19 patients. Only two of the
patients in these studies had multiple HIV-1 nef sequences from
brain tissues available. Currently, the assessment of HAD is
becoming more rigorous due to the use of the International HIV
Dementia Scale [56]. These tests, in combination with the
generation of large amounts of nef sequence data from patients
with well-documented cases of HAD could permit the develop-
ment of a system to identify HAD viruses through structural
analysis. The development of a biomarker for HAD development
could also aid in the development of drugs to target HAD-specific
viruses.
Supporting Information
Figure S1 Phylogenetic Analysis. All of the sequences used
in the study were incorporated into the phylogenetic tree. Each
patient and Uganda subtype A and D sequences are color-coded.
The tree was calculated using the protein sequences and the PAM
substitution matrix in MEGA 4.0. Bootstraping support values for
the major branches of the tree are superimposed.
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